secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001193125-23-053897
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q4 revenue $48.3M (+24% YoY); guides FY2023 $225-235M (+37-43%)
---------------------------------------------------------------------

- Full-year 2022 revenue $164.0M, up 28% YoY (34% constant currency); net income $2.5M.
- Q4 net income $3.7M vs loss $1.2M in Q4 2021; adjusted EBITDA $6.6M.
- 2023 revenue guidance $225-235M, including ~$20M from Luminex acquisition closed Feb 28.
- Acquired Luminex's Flow Cytometry and Imaging business; partnership with Bio-Rad.
- Cash and short-term investments $341.1M; 560 instrument placements in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/0001193125-23-053897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312523053897/d462230d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-053897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer